Châtillon, France, November 2, 2026 DBV Technologies to Participate in Upcoming November Investor Conferences DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today
Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children
Châtillon, France, October 27, 2026 DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 Company to host investor conference call and webcast at 5:00pm ET DBV
Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years The BLA is supported by the results
Châtillon, France, September 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (TRQX:DBVp) (the "Company"), a
Châtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company,
Châtillon, France, July 16, 2026 DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical
Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA for the VIASKIN®
Châtillon, France, July 14, 2026 DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 Company to host investor conference call and webcast at 5:00 p.m. ET DBV
AMF Regulated InformationChâtillon, France, July 6, 2026 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today issued
Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in
Châtillon, France, June 23, 2026 DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced that the Company has
Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical
